Sign In
Buy SLS
$11.81
+0.590 (+5.26%)
At Close: Aug 04, 2026
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
08:35am, Monday, 29'th Dec 2025
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
06:00am, Wednesday, 24'th Dec 2025
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The U. S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], dri
NEW YORK, Dec. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
12:20pm, Thursday, 04'th Dec 2025
/PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells
Stock Traders Purchase High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)
01:12am, Wednesday, 19'th Nov 2025
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS - Get Free Report) saw unusually large options trading activity on Tuesday. Stock investors acquired 15,545 call options on the company. This is an increa
SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript
05:36pm, Wednesday, 29'th Oct 2025
SELLAS Life Sciences Group, Inc. ( SLS ) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs October 29, 2025 10:00 AM EDT Company Participants Angelos Stergiou - Founder, Pre
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme
BlackRock just bought this stock with full voting control
07:28am, Saturday, 18'th Oct 2025
The world's largest investment management firm, BlackRock (NYSE: BLK), has disclosed a 5.4% ownership stake in biopharmaceutical company Sellas Life Sciences Group (NASDAQ: SLS).
Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026
09:18pm, Tuesday, 19'th Aug 2025
SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML applicabilit
- Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS''
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
08:06pm, Thursday, 31'st Jul 2025
SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
08:45am, Monday, 07'th Jul 2025
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the developmen
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Monday, 23'rd Jun 2025
Galena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
08:45am, Thursday, 05'th Jun 2025
New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year New appointments of Drs. Philip C. Amr
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
08:00am, Monday, 02'nd Jun 2025
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the
